Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $14.50

Shares of Rezolute, Inc. (NASDAQ:RZLT) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $14.50.

A number of analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating and set a $15.00 target price on shares of Rezolute in a research note on Monday, September 22nd. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Rezolute in a report on Thursday, September 18th. Wedbush reaffirmed an “outperform” rating and issued a $12.00 target price on shares of Rezolute in a report on Thursday, September 18th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Wednesday, September 3rd. Finally, Maxim Group boosted their price target on shares of Rezolute from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th.

Rezolute Stock Performance

NASDAQ:RZLT opened at $9.40 on Friday. The company has a market cap of $853.61 million, a PE ratio of -9.69 and a beta of 0.03. Rezolute has a 52-week low of $2.21 and a 52-week high of $9.56. The stock has a 50-day simple moving average of $7.12 and a 200 day simple moving average of $4.99.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, research analysts predict that Rezolute will post -0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RZLT. BNP Paribas Financial Markets acquired a new position in shares of Rezolute during the second quarter valued at about $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Rezolute during the second quarter worth $30,000. Legal & General Group Plc purchased a new stake in shares of Rezolute in the second quarter worth $32,000. Raymond James Financial Inc. purchased a new position in Rezolute in the 2nd quarter worth approximately $46,000. Finally, Jeppson Wealth Management LLC purchased a new position in shares of Rezolute in the 1st quarter worth about $35,000. Institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.